Latest

psychopharmacology

Featured Neurology Neuroscience Pain Psychology

·October 2, 2025·6 min read

Psilocybin Rewire Brain Circuits Tied to Pain and Mood

New research shows that psilocybin, the active compound in psychedelic mushrooms, can reduce both chronic pain and pain-related depression by modulating brain circuits rather than acting at the site of injury. In mouse studies, a single dose provided pain relief and mood benefits lasting nearly two weeks by targeting the anterior cingulate cortex.

This shows a mom and child with a swirly background.

Featured Neuroscience Psychology

·September 30, 2025·7 min read

Psilocybin Worsens Postpartum Depression Symptoms

New research shows psilocybin, often studied as a treatment for mental health disorders, may worsen symptoms of postpartum depression in mice. Mothers given the drug showed more anxiety, avoidance of their pups, and lasting depressive-like behaviors.

Featured Neurology Neuroscience

·September 17, 2025·4 min read

Psychedelics Show Promise for Healing Concussions and Brain Injuries

Traumatic brain injuries, including concussions, affect nearly 69 million people worldwide each year, yet treatments remain scarce. A new review highlights the potential of psychedelics such as psilocybin and 5-MeO-DMT to reduce harmful inflammation and enhance neuroplasticity after brain injury.

Featured Neuroscience Open Neuroscience Articles Psychology

·August 27, 2025·3 min read

Cannabis Linked to Reduced Insomnia and Anxiety

A new study suggests cannabis-based medical products may help people with insomnia sleep better over the long term. Across 124 patients followed for up to 18 months, participants consistently reported improved sleep quality, less anxiety and depression, and a better overall quality of life.

This is a visual representation of the 5-HT1A serotonin receptor.

Featured Neuroscience Psychology

·August 2, 2025·6 min read

Fat Molecule May Control How You Feel Emotion

Scientists have uncovered how the brain’s 5-HT1A serotonin receptor—vital in mood regulation—functions at the molecular level. This receptor, a common target of antidepressants and psychedelics, prefers certain signaling pathways no matter the drug, but drugs can still vary in how strongly they activate them.

Featured Neuroscience Psychology

·July 19, 2025·6 min read

More Than Serotonin: How Psychedelics Engage the Whole Brain

Classical psychedelics like LSD, psilocybin, and mescaline are known for activating the 5-HT2A serotonin receptor, but a new study reveals their effects go far beyond. Researchers profiled 41 psychedelics against over 300 human receptors and found potent activity at serotonin, dopamine, and adrenergic sites.

Featured Genetics Neuroscience Psychology

·July 19, 2025·7 min read

Why Antidepressants Work Better for Some

A meta-analysis of gene expression data from humans and rodents reveals key biological pathways influencing response to the antidepressant fluoxetine. The study highlights the role of immune-related pathways, including toll-like receptor signaling, and neural signal transduction mechanisms in distinguishing responders from non-responders.

This shows supplement bottles on a shelf.

Featured Neuroscience Psychology

·July 16, 2025·7 min read

Do Supplements Work for Depression? Some Do, Study Says

A comprehensive review of over 23,000 studies identified 64 over-the-counter (OTC) supplements and herbal products evaluated in clinical trials for depression. St John’s Wort, saffron, probiotics, vitamin D, and omega-3s showed the strongest evidence, while others like lavender, zinc, and chamomile showed promise but need more research.

Featured Neuroscience Psychology

·July 10, 2025·7 min read

Most Antidepressant Users Don’t Face Severe Withdrawal

The largest review of antidepressant withdrawal studies shows most people don’t experience severe symptoms when stopping these medications. Analyzing data from nearly 18,000 participants, researchers found the most common withdrawal symptoms were mild, including dizziness, nausea, and nervousness.

This shows a psychedelic brain and mushrooms.

Featured Neuroscience

·July 9, 2025·4 min read

Psilocybin Shows Promise as Anti-Aging Therapy

Psilocybin, the active compound derived from psychedelic mushrooms, significantly delayed cellular aging and extended lifespan in a preclinical study. Researchers observed a 50% increase in the lifespan of human skin and lung cells and a 30% increase in survival in aged mice treated with psilocybin.

Featured Neuroscience Psychology

·July 7, 2025·5 min read

Timing of Prozac Treatment Shapes Lasting Mood, Brain Changes

New research reveals that the developmental timing of fluoxetine (Prozac) treatment profoundly influences long-term mood and brain function. In a rodent model, early postnatal treatment in males led to persistent anxiety and depression-like behaviors, while adolescent treatment reduced these behaviors.

This shows the outline of two boys and leaves.

Autism Featured Neuroscience

·June 23, 2025·4 min read

CBD Shows Promise in Easing Behavior Challenges in Autism

Summary: A new clinical trial found that cannabidiol (CBD) is safe and potentially helpful in reducing problematic behaviors in boys with severe autism. While broad behavioral measures showed no significant differences from placebo, clinicians observed meaningful improvements in aggression, hyperactivity, and communication in many children taking CBD.